Edward M. Basile Sells 6,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

TransMedics Group Stock Down 0.4%

TransMedics Group stock opened at $121.81 on Friday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market capitalization of $4.12 billion, a P/E ratio of 129.59 and a beta of 1.91. The stock has a 50-day simple moving average of $82.91 and a 200-day simple moving average of $75.67.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analysts’ expectations of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.35 EPS. Equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors have recently added to or reduced their stakes in TMDX. Braidwell LP acquired a new position in TransMedics Group in the 4th quarter valued at about $57,493,000. Norges Bank acquired a new position in TransMedics Group during the 4th quarter worth approximately $22,861,000. Mackenzie Financial Corp increased its position in TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after purchasing an additional 349,403 shares during the period. Dimensional Fund Advisors LP increased its position in TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock worth $16,820,000 after purchasing an additional 253,624 shares during the period. Finally, Emerald Advisers LLC increased its position in TransMedics Group by 146.3% during the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock worth $23,176,000 after purchasing an additional 220,804 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Oppenheimer lifted their price target on TransMedics Group from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Friday, May 9th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Piper Sandler reissued an “overweight” rating and issued a $125.00 target price (up from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.